How I treat patients who mobilize hematopoietic stem cells poorly.

@article{To2011HowIT,
  title={How I treat patients who mobilize hematopoietic stem cells poorly.},
  author={Luen Bik To and Jean-Pierre L{\'e}vesque and Kirsten E. Herbert},
  journal={Blood},
  year={2011},
  volume={118 17},
  pages={
          4530-40
        }
}
Transplantation with 2-5 × 10(6) mobilized CD34(+)cells/kg body weight lowers transplantation costs and mortality. Mobilization is most commonly performed with recombinant human G-CSF with or without chemotherapy, but a proportion of patients/donors fail to mobilize sufficient cells. BM disease, prior treatment, and age are factors influencing mobilization, but genetics also contributes. Mobilization may fail because of the changes affecting the HSC/progenitor cell/BM niche integrity and… 

Figures and Tables from this paper

New agents in HSC mobilization
TLDR
The most recent developments in HSC mobilization agents are described and their potential impact in H SC transplantation is described.
Optimizing mobilization strategies in difficult-to-mobilize patients: The role of plerixafor.
  • H. Goker, Sezgin Etgul, Y. Buyukasik
  • Biology
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2015
How do we mobilize and collect autologous peripheral blood stem cells?
TLDR
The approach to autologous PBSC mobilization and collection that incorporates patient laboratory assessments, monitoring of the collection yields, and judicious use of plerixafor as well as various patient support and education programs has resulted in an increase in the collection success rate and a decrease in the mean number of collection days.
Management of mobilization failure in 2017.
  • S. Namdaroğlu, S. Korkmaz, F. Altuntaş
  • Medicine
    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • 2017
Plerixafor for mobilization of blood stem cells in autologous transplantation: an update
TLDR
Grafts collected after plerixafor appear to contain more lymphoid cells than the grafts collected without it, and whether this affects post-transplant outcomes such as immune reconstitution and risk of relapse needs to be evaluated.
Stable colony-stimulating factor 1 fusion protein treatment increases hematopoietic stem cell pool and enhances their mobilisation in mice
TLDR
Competitive transplant assays demonstrated that pre-treatment of donors with CSF1-Fc increased the number and reconstitution potential of HSPC in blood following a HSC mobilising regimen of G-CSF treatment, and indicated that CSF 1- Fc conditioning could represent a therapeutic strategy to overcome poor HSCMobilisation and subsequently improve HSC transplantation outcomes.
Stable colony stimulating factor 1 fusion protein treatment increases HSC pool and enhances their mobilisation in mice
TLDR
Recovery from Fc-modified colony stimulating factor-1 (CSF1-Fc) treatment was accompanied by an increase in total haematopoietic stem cells, indicating that CSF 1 Fc conditioning could represent a therapeutic strategy to overcome poor HSC mobilisation and subsequently improve autologous or heterologous HSC transplantation outcomes.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 164 REFERENCES
Management strategies for the hard-to-mobilize patient
  • P. Stiff
  • Medicine
    Bone Marrow Transplantation
  • 1999
TLDR
In this trial, stem cell mobilization with granulocyte colony-stimulating factor (G- CSF) alone was compared to mobilization with G-CSF combined with stem cell factor (SCF) in heavily pretreated patients with Hodgkin's and non-Hodgkin’s lymphoma.
Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization.
  • M. Watts, A. Sullivan, D. Linch
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1998
TLDR
In most patients whose PBSC collection contains less than 1 x 10(5)/kg GM-CFC, the use of bone marrow cells does not improve engraftment, which suggests that poor PBSC mobilization usually indicates poor marrow function.
Phase I trial of parathyroid hormone to facilitate stem cell mobilization.
  • K. Ballen, E. Shpall, T. Spitzer
  • Biology, Medicine
    Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • 2007
First Results of a Phase-II Study with the New CXCR4 Antagonist POL6326 to Mobilize Hematopoietic Stem Cells (HSC) In Multiple Myeloma (MM)
TLDR
Testing to what extent POL6326 can be used as monotherapy, infused over 1 or 2h, to mobilize sufficient HSC for subsequent autologous transplantation in newly diagnosed myeloma patients found it safe and very well tolerated.
Stem cell factor and high-dose twice daily filgrastim is an effective strategy for peripheral blood stem cell mobilization in patients with indolent lymphoproliferative disorders previously treated with fludarabine: results of a Phase II study with an historical comparator
TLDR
G- CSF improves PBSC mobilization efficacy after fludarabine exposure, over mobilization using G-CSF as the mobilizing cytokine, and this combined growth factor strategy is a preferred mobilization method for fludARabine-exposed patients.
Kinetics of committed and primitive blood progenitor mobilization after chemotherapy and growth factor treatment and their use in autotransplants.
TLDR
Peripheral blood cells collected by leukapheresis after progenitor mobilization with chemotherapy and growth factors have been used successfully to replace marrow autografts in protocols requiring stem-cell support, and patients who were transplanted over a 7-year period with PBCs alone are presented.
Pharmacological inhibition of EGFR signaling enhances G-CSF–induced hematopoietic stem cell mobilization
TLDR
A previously unknown signaling pathway regulating stem cell mobilization is revealed and a new pharmacological approach is provided for improving HSPC mobilization and thereby transplantation outcomes.
Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization
TLDR
It is concluded that patients who fail to mobilize PBSC should be evaluated for second-line BM harvest, and this approach may preserve the therapeutic option of HDCT for these patients.
A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor
TLDR
This approach helped to control the overall cost of HSC collections for the BMT program by decreasing the need for remobilization, reducing the number of collection days and avoiding the use of plerixafor in all patients.
Single-dose pegfilgrastim for the mobilization of allogeneic CD34+ peripheral blood progenitor cells in healthy family and unrelated donors.
TLDR
The study shows that collection of allogeneic PBPC after administration of a single dose of pegfilgrastim is feasible and the toxicity profile, graft composition and impact on the recipients' outcome need further investigation.
...
1
2
3
4
5
...